Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
“Ms Mohamed said she had taken a lateral flow test and was satisfied she didn’t have Covid, but the Covid rules effective today and on April 2, 2021 require that in order to travel abroad one must obtain a PCR test. A lateral flow test is not sufficient or acceptable to fly abroad.
“She knew what she was doing, she knew a PCR test was required as she found a friend to make a false document for her.”
https://www.google.co.uk/amp/s/www.standard.co.uk/news/crime/sohyla-mohamed-pcr-covid-test-fly-doctor-fraud-certificate-b935236.html%3famp
Ha! Bet you did. It’ll come as no surprise I dislike this government, doesn’t mean I am a left wing looney or anti capitalist. Just means I think for myself rather than choosing political colours for life like a football team.
And a swipe at you, You contribution in all this.. you are just a person sitting on your backside looking to take advantage as are we all. None should go so far as calling him an idiot for his beliefs which actually are incorrect. Far left loonies wouldn’t sub contract to a private company seeking to make profit out of people’s health. Take a good look at yourself before you speak!
No, he is not planning to sell Paraytec’s device to the U.K. government you Tool! He employer is Sheffield Uni and is sub contracted in to complete a task. The device belongs to Paraytec. Carl can say and do as he pleases as far as I am concerned, it is Sheffield Uni he has to answer too. By the way, just because he criticises the government of the day (most people in the care for people professions do) that does not make him a left wing looney and anti capitalist. Good grief!
I would suggest you step back and ask a few basic questions. How do economies around the world work? Do they use one brand/type of product? How many brands of LFT’s are in circulation?
Why does BRH’s product have to be the only product available in its scope and the ultimate product to succeed? If the device does what it says on the tin (unlike many competitors beyond the lab) it will have a global market at its feet. It needs 1% 2% even 3% of of this multi billion market to become worth multiples of its current valuation, but unlike many competitors, the device also has huge scope in other huge global markets it will tap into, such as the announced Sepsis market, here we currently have zero competition.
If it can be labelled with an Aptamer, this device can see it. The potential is unlimited.
Ok, I’ll answer your question Rocquet
This investment company owns the company which have been working on a super quick test which is highly accurate and already meeting MHRA standards, matrix/pooling capability, future proof to any variants or any other pathogens thanks to endless design capabilities of Aptamers, currently challenging PCR gold standards and already exceeded them in speed and sample size, which makes it more user friendly in real world settings. There is an ongoing need to save lives and keep economies open at global level which the U.K. Government acknowledges itself that the U.K. is at risk due to possible variants mutating rendering the current vaccination program void therefore taking us back to square one.
Let’s add the other obvious elephant in the room, a huge global market in Sepsis as announced this device will target and currently without any competition at all yet strange enough it is an expected outcome of Covid infection let alone the huge unmet market globally in normal times.
It will be able to identify certain cancers in minutes/seconds because some of these can now be labelled with Aptamers.
Support food safety to provide human health, with a low-cost method for contaminant detection.
Aptamers and Aptamer-Coupled Biosensors to Detect Water-Borne Pathogens
Aptamer-Based Biosensors for Environmental Monitoring
The list goes on and on..
And you say this isn’t worth even the current £16m valuation? Have a word with yourself! We have a user friendly fast accurate mobile automated device which the use of Aptamer’s have been waiting for.
The surge in coronavirus cases in Bolton has been driven by a huge spike in cases among schoolchildren, official data shows.
The number of positive tests among children under the age of 14 has tripled in a week, figures released by Public Health England revealed
There have also been large increases among younger adults, who might have been exposed to the virus through their school age children, although work places could also be a factor.
https://www.google.co.uk/amp/s/www.manchestereveningnews.co.uk/news/greater-manchester-news/coronavirus-rates-teenagers-bolton-surge-20592303.amp
It depends on how serious governments across the world want to ensure this never happens again. LFT’s leave unacceptable holes, PCR’s are too slow. The problem has not been resolved yet using these options therefore lockdowns remain the ultimate answer.
I think the quiet is a good sign. You only need shout if no one is listening. RNS states it is passing data ‘requested’ by partners combined with an updated time line and no further mention of taking the test to market ourselves. The conversion from lab to commercial product had to be at least end of June as per the advertised job description back in March. The partners mentioned have to be considered to be Malvern Panalytical and Pion and again as I’ve mentioned before,!the jury is out on whether GSK, Astra and Fuji are classed as partners as suggested on Paraytec’s website when considering what this small device was initially devised for in the first place prior to Covid hitting the world. No, I don’t think GSK and Astra would ever sell Covid tests but Fuji could easily meet a global scale if required. I have put out there the news article that they are working with at least the U.K. government to help create new innovative Covid tests at scale and make the U.K. a leader. The fact is Paraytec have worked with these giants using its Actipix.
I wouldn’t worry about seconds. It’s a 2 min Antigen test targeting the commercial market. Ours is also 2 mins, but we also can tackle the matrix/pool testing which for example, a family of 4 would require one test 2 mins v 4 x 2 min tests and 4 x costs..
Example. - 1 £25 @ 2 mins v 4 x £25 @ 8 mins.
Jury is out regarding its accuracy scope after reading the small print.
Well why not, it could! Up/Down.. Who really knows? None of you on here actually know either side of your playing field. However, I don’t see the difference between talking a shareprice up or down. Only fools listen to any price predictions from strangers on a public BB. Either way, scaring people to buy through fear of missing out is equally as bad as scaring people to sell through fear of losing money. Same fish swimming in a bowl in different directions causing havoc.
I’m remembering the U.K. Government consultation regarding putting tests through more robust testing themselves as 70% of rapid kits don’t do what they say they do and also most sensitivity and specificity is affected in real world conditions.
Rocky500, worth reading the small print in this 25 second - 2 min test
It is possible for a person to test too early or too late during COVID-19 infection to make an accurate diagnosis using the Pelican COVID-19 Ultra-Rapid Mobile Test.
This test is to be performed only using saliva specimens collected by a healthcare professional for an individual aged 2 years or older. This test is authorized for use in these individuals regardless of whether they have symptoms or other epidemiological reasons to suspect a COVID-19 infection.
A negative test result for this test means that SARS- CoV-2 antigens were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. The amount of antigen in a sample may decrease as the duration of illness increases.
https://docs.pelicandetect.com/EU%2B-%2BFact%2BSheet%2Bfor%2BHealthCare%2BProviders.pdf
Baffyman - My understanding of Antigen tests.
Antigen tests are immunoassays that detect the presence of a specific viral antigen, which implies current viral infection.
If AVCT are doing something similar as Paraytec using Affimers rather than Aptamers than great! I wasn’t aiming shots at AVCT. It is at Antigen testing in general. Perhaps because great minds think alike, it is why both tests appear to stand out above others in the areas they are targeting? (Infectious v infected) One gets praise, the other gets ridicule.
Baffyman, argue with those at the British Medical Journal.
‘Although controls within assays minimise errors, technical problems during sample collection, processing, or reporting can give false results. Lateral flow tests produce very few false positive results, and in a low prevalence setting these can be detected by confirmatory PCR testing. False negative results are more concerning. Besides technical errors, they can arise in people tested during the 5-7 day incubation period before the viral antigen shed in the nose and throat is sufficient to be detected, usually 1-2 days before symptom onset. Taking swabs requires skill, and swabs taken by untrained individuals are more likely to give false negative results. False negatives might create a false sense of security, paradoxically increasing transmission risk.
https://www.bmj.com/content/372/bmj.n208
No, Antigens are molecules capable of stimulating an immune response (the anti bodies) This immune response can take anything from 5-12 days before antigen tests are capable of reading them. This is why they are cr@p for early detection of the virus and geared to find ‘infectious’ people, not all that are ‘infected’
No Antigen test can EVER beat a test looking for Virus particles that cause antibodies to be created giving Antigen tests something to look for which can take from 5-12 days for the body to produce. It is impossible!
Paraytec’s device will beat this 25 second test by a number of DAYS... we are not quibbling over seconds or minutes here.